Neurocrine Biosciences In... (NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Kyle Gano - CEO & Director Sanjay Keswani - Chie...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Matthew Abernethy - Chief Financial Officer Eric Benevich - Chie...

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang f...

Neurocrine (NBIX) Q2 Revenue Jumps 17%

Neurocrine Biosciences' Ingrezza still generates most of its total revenues. This is their blockbuster drug. I also believe Ingrezza is well-positioned for future growth with new label additions, and ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants n - Corporate Participant Eiry Wyn Roberts - Corporate Participant Strategic ...

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Stree...

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.63 per share a year ago.

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option ...

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.